Sweden
· Delayed Price · Currency is SEK Level Bio AB Statistics
Total Valuation
Level Bio AB has a market cap or net worth of SEK 17.05 million. The enterprise value is 15.09 million.
| Market Cap | 17.05M |
| Enterprise Value | 15.09M |
Important Dates
The next estimated earnings date is Thursday, October 24, 2024.
| Earnings Date | Oct 24, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Level Bio AB has 63.40 million shares outstanding.
| Shares Outstanding | 63.40M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.03% |
| Float | 43.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.24 |
| EV / Sales | 0.63 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.30 |
Financial Position
The company has a current ratio of 1.07
| Current Ratio | 1.07 |
| Quick Ratio | 0.49 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -282.51 |
Financial Efficiency
Return on equity (ROE) is -111.88% and return on invested capital (ROIC) is -71.05%.
| Return on Equity (ROE) | -111.88% |
| Return on Assets (ROA) | -41.31% |
| Return on Capital (ROIC) | -71.05% |
| Revenue Per Employee | 1.84M |
| Profits Per Employee | -936,846 |
| Employee Count | 13 |
| Asset Turnover | 1.28 |
| Inventory Turnover | 2.59 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -53.14% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -53.14% |
| 50-Day Moving Average | 0.33 |
| 200-Day Moving Average | 0.39 |
| Relative Strength Index (RSI) | 44.91 |
| Average Volume (20 Days) | 20,492 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Level Bio AB had revenue of SEK 23.92 million and -12.18 million in losses.
| Revenue | 23.92M |
| Gross Profit | 11.64M |
| Operating Income | -12.37M |
| Pretax Income | -12.40M |
| Net Income | -12.18M |
| EBITDA | -11.23M |
| EBIT | -12.37M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
| Cash & Cash Equivalents | 1.96M |
| Total Debt | n/a |
| Net Cash | 1.96M |
| Net Cash Per Share | 0.03 |
| Equity (Book Value) | 4.80M |
| Book Value Per Share | n/a |
| Working Capital | 630,000 |
Cash Flow
In the last 12 months, operating cash flow was -6.53 million and capital expenditures -42,500, giving a free cash flow of -6.57 million.
| Operating Cash Flow | -6.53M |
| Capital Expenditures | -42,500 |
| Free Cash Flow | -6.57M |
| FCF Per Share | -0.10 |
Margins
Gross margin is 48.66%, with operating and profit margins of -51.73% and -50.91%.
| Gross Margin | 48.66% |
| Operating Margin | -51.73% |
| Pretax Margin | -51.81% |
| Profit Margin | -50.91% |
| EBITDA Margin | -46.95% |
| EBIT Margin | -51.73% |
| FCF Margin | -27.47% |
Dividends & Yields
Level Bio AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | -38.53% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |